TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00052910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study: NCT00158223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide
Description: Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
Study: NCT04588831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthguard
Description: Protective device for orofacial complex for patients playing contact sports

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthguard
Description: Protective device for orofacial complex for patients playing contact sports
Study: NCT00052910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT01708590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered subcutaneous (SC)
Study: NCT00052910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given 5 days a week for 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 5 weeks
Study: NCT01708590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered subcutaneous (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered subcutaneous (SC)
Study: NCT01593241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved node RT
Description: Involved node RT
Study: NCT02906241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams
Description: This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physicians: Educational Module
Description: Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
Study: NCT02135627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
Study: NCT04588831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthguard
Description: Protective device for orofacial complex for patients playing contact sports
Study: NCT00045175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT02135627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current standard therapy
Study: NCT03138018

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Description: Neuropsychological tests

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Description: Neuropsychological tests

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Description: Neuroimaging biomarkers of neurodegeneration

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Description: Neuroimaging biomarkers of neurodegeneration
Study: NCT01757977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double lumen endotracheal tube placement and use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double lumen endotracheal tube placement and use
Study: NCT02604810

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IGIV-C 10%
Description: IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20%
Description: IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
Study: NCT00442767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide + Insulin
Description: 30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
Study: NCT02017899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB
Study: NCT02827812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive evaluation
Description: At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive evaluation
Description: At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Intervention at home
Description: A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Intervention at home
Description: A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based telemedicine program
Description: 1. A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~2. A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences.
Study: NCT02089932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02559635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowel stimulation
Description: Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestle Resource
Description: Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
Study: NCT00724659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
Study: NCT02017899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04072172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mole Freckle Pen
Description: Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
Study: NCT02836483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg, QD
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 400mg, BID
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg, BID
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tubes 3~5Tablet, QD
Description: Oral administration
Study: NCT02808897

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard drainage
Description: One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (Fr) shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Tube Clearance drainage
Description: One (1) PleuraFlow chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 Fr shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
Study: NCT02836483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyvox 600mg, BID
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 1200mg, QD
Description: Oral administration
Study: NCT03940560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duramesh Suturable Mesh
Description: Use of Duramesh Suturable Mesh for internal load bearing closures
Study: NCT00558636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib + Paclitaxel + Carboplatin
Description: Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), \[400 mg, (2 tablets x 200 mg each) orally, twice daily\] on Study Days 2-19 and paclitaxel (175 mg/m\^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Paclitaxel + Carboplatin
Description: Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m\^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
Study: NCT00716001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine
Study: NCT02663154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatherapy inhaler
Description: Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline inhaler
Description: Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
Study: NCT03679390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
Study: NCT02523287

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: Randomized assignment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: Randomized assignment
Study: NCT02564029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06372865 and placebo for lorazepam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: 2 mg single oral dose
Study: NCT04063072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
Study: NCT03625154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ankle open reduction internal fixation
Description: Open Reduction and Internal Fixation with plates and screws

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non operative management
Description: closed reduction and splinting followed by progressive weight bearing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non operative management
Description: closed reduction and splinting followed by progressive weight bearing
Study: NCT00903370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MVS
Description: All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
Study: NCT02523287

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Randomized assignment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Randomized assignment
Study: NCT00903370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MVS
Description: All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
Study: NCT03909555

Intervention type: OTHER
Intervention: Complications assessment
Description: Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.

Intervention type: OTHER
Intervention: Complications assessment
Description: Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.
Study: NCT04319419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement with micronutrients
Description: Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Group received nutrition education program during 6 months
Study: NCT02227849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (TA-7284)
Description: The patients will receive Canagliflozin orally for 52 weeks
Study: NCT05261659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy and Targeted memory reactivation during REM sleep
Description: Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
Study: NCT04116593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
Study: NCT01321008

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg by mouth daily on Days 1-5 of a 21 day cycle.